Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity.
View / Open Files
Authors
Davis, Daniel A
Miller, Dave A
Santitewagun, Supawan
Zeitler, J Axel
Su, Yongchao
Williams, Robert O
Publication Date
2021-12Journal Title
Int J Pharm X
ISSN
2590-1567
Publisher
Elsevier BV
Volume
3
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Davis, D. A., Miller, D. A., Santitewagun, S., Zeitler, J. A., Su, Y., & Williams, R. O. (2021). Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity.. Int J Pharm X, 3 https://doi.org/10.1016/j.ijpx.2021.100092
Abstract
We seek to further addresss the questions posed by Moseson et al. regarding whether any residual crystal level, size, or characteristic is acceptable in an amorphous solid dispersion (ASD) such that its stability, enhanced dissolution, and increased bioavailability are not compromised. To address this highly relevant question, we study an interesting heat- and shear-labile drug in development, LY3009120. To study the effects of residual crystallinity and degradation in ASDs, we prepared three compositionally identical formulations (57-1, 59-4, and 59-5) using the KinetiSol process under various processing conditions to obtain samples with various levels of crystallinity (2.3%, 0.9%, and 0.1%, respectively) and degradation products (0.74%, 1.97%, and 3.12%, respectively). Samples with less than 1% crystallinity were placed on stability, and we observed no measurable change in the drug's crystallinity, dissolution profile or purity in the 59-4 and 59-5 formulations over four months of storage under closed conditions at 25 °C and 60% humidity. For formulations 57-1, 59-4, and 59-5, bioavailability studies in rats reveal a 44-fold, 55-fold, and 62-fold increase in mean AUC, respectively, compared to the physical mixture. This suggests that the presence of some residual crystals after processing can be acceptable and will not change the properties of the ASD over time.
Keywords
Degradation, Bioavailability Enhancement, Amorphous Solid Dispersion, Residual Crystallinity, Kinetisol Processing, Seed Crystallinity
Identifiers
34977559, PMC8683684
External DOI: https://doi.org/10.1016/j.ijpx.2021.100092
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333586
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk